[Results of an anti-hepatitis-B vaccination in a population at risk].
135 subjects, belonging to the sanitary staff and the dialyzed patients (high-risk classes) of the Ospedale Maggiore in Crema, have been vaccinated against hepatitis B with Hevac B vaccine produced by Pasteur firm. We have followed the vaccination protocol advised by the producer firm: subcutaneous administration in the deltoid region of three doses at one month intervals. One year after the third dose a further one was administered. Each dose of vaccine contains 5 micrograms of purified and inactivated HBsAg. We have investigated the presence of HBsAb, as protection standard, using EIA Abbott. 30 days after the first dose, HBsAb was present in 7.3% of the subjects; this percentage increased until 26.5% after the second dose and until 77.7% after the third one. One month after the fourth dose 95.6% appeared serologically protected against HBV. Secondary reactions to vaccine have been negligible.
Stellato
M
M
Ospedale Maggiore, Crema (CR).
Carbi
S
S
Tosolini
S
S
D000328:Adult; D005069:Evaluation Studies as Topic; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage / Q000276:immunology; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D010564:Personnel, Hospital; D006435:Renal Dialysis; D012307:Risk Factors; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines
Risultati di una vaccinazione anti-epatite B in una popolazione a rischio.